Abstract

Since we last discussed appetite suppressants¹ their limitations have become better understood, and this prompts a reassessment of their place in the management of obesity. Centrally acting appetite suppressant drugs or anorectics reduce physiological hunger by an action on the brain, presumably interfering with the pathways concerned in the regulation of food intake.² Methylcellulose (Cellucon, Celevac, Cologel) and sterculia (Prefil) act by filling the stomach and are less effective clinically but are safe.³ This article discusses only those drugs with central actions.